Expecting worse cognitive performance and higher tumor connectivity in patients with more invasive glioma types, IDH wildtype patients tended in fact to show worse attentional performance and higher Tu-EL FC, but with statistical subanalyses of prognostically differing tumor types (based on IDH mutation status) being not feasible in our study due to the limited sample size. The gene discussed is IDH1; the disease is central nervous system cancer.